Brookfield Wealth Solutions Ltd (BNT) ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Brookfield Wealth Solutions Announces Third Quarter Results and Declares Regular Quarterly Distribution

BROOKFIELD, NEWS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Brookfield Wealth Solutions (NYSE, TSX: BNT) today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bentley Pharmaceuticals' Stockholders Approve Merger Agreement

Bentley Pharmaceuticals, Inc. (NYSE: BNT) (?Bentley? or the ?Company?) announced today that its stockholders have approved the...

Bentley Pharmaceuticals Inc - Termination of Registration of a Class of Security under Section 12(g) (15-12G)

OMB APPROVAL OMB Number: 3235-0167 Expires: November 30, 2010 Estimated average burden hours per response 1.50 UNITED STATES SECURITIES AND...

Bentley Pharmaceuticals Inc - Current report filing (8-K)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT...

Bentley Pharmaceuticals Notifies NYSE of Intention to Delist Common Stock

Bentley Pharmaceuticals, Inc. (NYSE: BNT) (?Bentley? or the ?Company?) announced today that it notified the New York Stock...

Bentley Pharmaceuticals Inc - Current report filing (8-K)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT...

Bentley Pharmaceuticals Inc - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Bentley Pharmaceuticals Inc - Current report filing (8-K)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT...

Bentley Pharmaceuticals Inc - Confidential Treatment Order (CT ORDER)

Bentley Pharmaceuticals Inc - Confidential Treatment Order (CT ORDER)

Bentley Pharmaceuticals Inc - Proxy Statement - Merger or Acquistion (definitive) (DEFM14A)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

Bentley Pharmaceuticals Inc - Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION...

Bentley Board Approves Spin-off of Drug Delivery Business

The board of directors of Bentley Pharmaceuticals, Inc. (NYSE: BNT) today approved the spin-off of its drug delivery business...